Feed SAVA
SA

Cassava Sciences, Inc.

SAVA · NASDAQ

$1.96 -1.76% (-$0.04)
Piotroski F-Score Weak
1/9
Valuation
-
N/A
EV/EBITDA N/A
P/S N/A
P/B N/A
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A
ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A
Current ratio N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
50 /100
Moderate
Beta -0.84x
EPS volatility N/A
Profitable years N/A

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o SAVA
Online

O podjetju

Cassava Sciences, Inc. (SAVA) is a biotechnology company focused on research and development of therapeutic treatments for neurodegenerative diseases. The company's primary goal is to discover innovative therapies targeting Alzheimer's disease, one of the most devastating cognitive impairing illnesses. Cassava Sciences is developing a drug known as Simufilam, which has undergone clinical trials and has shown promising results in improving cognitive functions in Alzheimer's disease patients. Investing in Cassava Sciences' stock may present an attractive opportunity for investors who closely follow advancements in neurodegenerative disease treatments and seek innovative companies with potential in the biotechnology field.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Richard Jon Barry

Employees

30

Headquarters

Austin

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.